- Home
- ISPO vs AKTX Comparison
ISPO vs AKTX Comparison
Compare ISPO & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPO
- AKTX
- Stock Information
- Founded
- ISPO 2010
- AKTX N/A
- Country
- ISPO United States
- AKTX United States
- Employees
- ISPO N/A
- AKTX N/A
- Industry
- ISPO Blank Checks
- AKTX Biotechnology: Pharmaceutical Preparations
- Sector
- ISPO Finance
- AKTX Health Care
- Exchange
- ISPO Nasdaq
- AKTX Nasdaq
- Market Cap
- ISPO 39.0M
- AKTX 34.7M
- IPO Year
- ISPO N/A
- AKTX N/A
- Fundamental
- Price
- ISPO $6.99
- AKTX $1.19
- Analyst Decision
- ISPO Buy
- AKTX
- Analyst Count
- ISPO 2
- AKTX 0
- Target Price
- ISPO $10.50
- AKTX N/A
- AVG Volume (30 Days)
- ISPO 71.9K
- AKTX 67.9K
- Earning Date
- ISPO 03-04-2025
- AKTX 02-15-2025
- Dividend Yield
- ISPO N/A
- AKTX N/A
- EPS Growth
- ISPO N/A
- AKTX N/A
- EPS
- ISPO N/A
- AKTX N/A
- Revenue
- ISPO $287,451,000.00
- AKTX N/A
- Revenue This Year
- ISPO N/A
- AKTX N/A
- Revenue Next Year
- ISPO N/A
- AKTX N/A
- P/E Ratio
- ISPO N/A
- AKTX N/A
- Revenue Growth
- ISPO N/A
- AKTX N/A
- 52 Week Low
- ISPO $3.11
- AKTX $0.90
- 52 Week High
- ISPO $9.31
- AKTX $4.40
- Technical
- Relative Strength Index (RSI)
- ISPO 87.48
- AKTX 47.06
- Support Level
- ISPO $3.26
- AKTX $1.13
- Resistance Level
- ISPO $3.75
- AKTX $1.27
- Average True Range (ATR)
- ISPO 0.49
- AKTX 0.12
- MACD
- ISPO 0.31
- AKTX 0.03
- Stochastic Oscillator
- ISPO 95.40
- AKTX 44.92
About ISPO Inspirato Incorporated
Inspirato Inc is a luxury travel subscription luxury travel company that provides exclusive access to a managed and controlled portfolio of curated vacation options, delivered through a model designed to ensure the service, certainty, and value that discerning customers demand. The Inspirato portfolio includes branded luxury vacation homes, accommodations at five-star hotel and resort partners, and custom travel experiences. It has a geographic location in the United States and Outside the United States. It generates the majority of its revenue from the United States.
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).